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Lysosome-related organelleHermansky–Pudlak syndrome (HPS) is a group of rare autosomal recessive disorders characterized by
oculocutaneous albinism, a bleeding tendency, and sporadic pulmonary ﬁbrosis, granulomatous colitis or
infections. Nine HPS-causing genes have been identiﬁed in humans. HPS-1 is the most severe subtype with
a prevalence of ~1/1800 in northwest Puerto Rico due to a founder mutation in the HPS1 gene. Mutations
in HPS genes affect the biogenesis of lysosome-related organelles such as melanosomes in melanocytes and
platelet dense granules. Two of these genes (HPS1 and HPS4) encode the HPS1 and HPS4 proteins, which assem-
ble to form a complex known as Biogenesis of Lysosome-related Organelle Complex 3 (BLOC-3). We report the
identiﬁcation of the interacting regions in HPS1 and HPS4 required for the formation of this complex. Two
regions in HPS1, spanning amino acids 1–249 and 506–700 are required for binding to HPS4; themiddle portion
of HPS1 (residues 250–505) is not required for this interaction. Further interaction studies showed that the
N-termini of HPS1 and HPS4 interact with each other and that a discrete region of HPS4 (residues 340–528)
interacts with both the N- and C-termini of the HPS1 protein. Several missense mutations found in HPS-1
patients did not affect interactionwithHPS4, but somemutations involving regions interactingwithHPS4 caused
instability of HPS1. These observations extend our understanding of BLOC-3 assembly and represent an impor-
tant ﬁrst step in the identiﬁcation of domains responsible for the biogenesis of lysosome-related organelles.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Hermansky–Pudlak syndrome (HPS) [MIM# 203300] is a group of
autosomal recessive conditions characterized by hypopigmentation
and a bleeding tendency caused by defective biogenesis of lysosome-
related organelles such as melanosomes and platelet dense granules
[1–4]. Some HPS subtypes develop other complications such as pulmo-
nary ﬁbrosis and/or granulomatous colitis [3]. In humans, nine different
genes have been found to cause HPS but inmouse, mutations in at least
16 genes causeHPS-like phenotypes [5–12]. Themajority of these genes
encode proteins of unknown structure and function. Others encode
subunits of well-characterized complexes involved in vesicular trafﬁck-
ing such as AP-3 and HOPS [6]. HPS gene products have been identiﬁedd organelles; DUF, domain of
edium; EGFP, enhanced green
tinin; HPS, Hermansky–Pudlak
sociated membrane protein 2;
RT-PCR, reverse transcriptase-
+1 787 764 8209.
).
t of Internal Medicine, Division
l rights reserved.as subunits of at least three multi-protein complexes named BLOC
(Biogenesis of Lysosome-relatedOrganelles Complex) -1 to -3. The pre-
cise functions of BLOC complexes have not been well established, al-
though physical interactions between components of these complexes
have been suggested and deﬁned [13].
In particular, BLOC-3 consists of two cytosolic proteins, HPS1 and
HPS4 [14–17].
Patients withmutations in either subunit of the heterodimer general-
ly develop fatal lung ﬁbrosis in their fourth to ﬁfth decade of life or earlier
in some cases [3]. A frameshift mutation consisting of duplication of a 16
base pairs sequence in exon15 of theHPS1 gene is themost commonmu-
tation in the northwest region of the island of Puerto Rico [5]. The HPS1
gene encodes a 700 amino acids-long protein with a molecular weight
of 79.3 kDa [5], whereas HPS4 codes for a 76.9-kDa polypeptide of 708
amino acids. Both proteins exhibit a cytosolic distribution with approxi-
mately 10% associated tomembranes, but association to a speciﬁc cellular
organelle has not been established [14–16]. Co-immunoprecipitation of
epitope-tagged and endogenous proteins demonstrated a tight interac-
tion between these two proteins. However, this interaction was not
evident on yeast two hybrid analysis, which suggested that additional
components of BLOC-3 may exist [14–16]. Rab9, a small GTPase that lo-
calizes in late endosomes, was recently shown to interact with BLOC-3
[17]. Bioinformatic analyses have suggested that HPS proteins exhibit
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intracellular vesicular trafﬁcking [18,19]. In particular, HPS4 contains a
conserved N-terminal domain of approximately 200 amino acids, which
has been termedCHiPS (for CCZ1–HPS4) [18]. In addition, a central region
of approximately 200 residues of HPS1 has homology to the C-terminal
domain of members of the PAT family (for Perilipin, Adipophilin, and
TIP47 (tail-interacting protein of 47 kDa) [18]. In order to elucidate and
understand themolecular function of the BLOC-3 complex, it is important
to assess the organization and interacting regions critical for complex
formation.
In this study, we identiﬁed the regions in HPS1 and HPS4 required
for the formation of BLOC-3. Point mutations in the interacting re-
gions destabilize the proteins, suggesting that they are important
for complex stability. These observations extend our understanding
of BLOC-3 assembly and represent an important ﬁrst step in identify-
ing novel protein domains responsible for the biogenesis of lysosome-
related organelles.
2. Materials and methods
2.1. Antibodies
The following mouse monoclonal antibodies were used: anti-Myc
(9E10), anti-GFP (B-2) and anti-V5 (Santa Cruz Biotechnology), hemag-
glutinin (HA) tag (HA.11; Covance, Princeton, NJ), anti-Akt, anti-
Phospho Akt (Cell Signaling Technology, Beverly, MA), anti-HPS1
(hHPS5, a gift of Dr. Richard Spritz, University of Colorado) and the rab-
bit polyclonal antibody anti-LAMP2 (Abcam), anti-HPS4 (a gift of Dr.
Juan Bonifacino). Donkey Alexa-488 anti-mouse IgG and Alexa-555
anti rabbit IgG were purchased from Molecular probes (Eugene, OR).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgGs
were purchased from Amersham Biosciences, Piscataway, NJ.
2.2. Cell culture and transfections
Normal (GM00037H) and Puerto Rican HPS1 16 bp duplication mu-
tant ﬁbroblasts (GM14609) were obtained from the Coriell Institute for
Medical Research and maintained in MEM Eagle-Earle supplemented
with 15% fetal bovine serum (FBS). HeLa and M1 cells (a gift of Dr. Juan
Bonifacino, NICHD) were maintained in Dulbecco's Modiﬁed Eagle's
medium (Invitrogen, Carlsbad, CA) with 10% (v/v) heat-inactivated fetal
bovine serum (FBS; Invitrogen). For the stably transfected M1
clone 26, expressing Myc3–HPS4, the medium was supplemented
with 600 μg/ml G-418. All cell cultures were supplemented with
2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomy-
cin and grown in a humidiﬁed incubator with 5% CO2 at 37 °C.
Transfections were carried out using the Lipofectamine™ 2000 re-
agent (Invitrogen) according to the manufacturer's instructions.
2.3. cDNA tissue panel PCR
For tissue-speciﬁc expression studies of alternatively spliced RNA
isoforms, human multiple tissue cDNA panels (human MTC panels I
and II) were purchased from Clontech/BD Biosciences. We designed
a primer set for PCR ampliﬁcation of the regions where the splice
variant(s) differed and generated products of different lengths. The
forward primer 5′-GGCAACTTCCTGTATGTCCTTCACCTG-3′ was locat-
ed before exon 5 and the reverse primer 5′-CTGCTATCTGAAGGGC
ATCC-3′ hybridizes after exon 9.
2.4. DNA constructs and mutations
The pCI–HA3–HPS1 and pCI–Myc3–HPS4 vectors were generated as
described [14]. The full length coding sequence ofHPS1was obtained by
PCR ampliﬁcation of cDNA and cloned in frame into the Xho1 and EcoR1
sites of the pEGFP1-C1 vector (BD Biosciences Clontech, Palo Alto, CA).Mutagenesis of expression constructs was performed using the
QuikChange Site-DirectedMutagenesis kit (Stratagene) as recommended
by the manufacturer. To generate the pCI-Myc3–HPS4340–708 and pCI-
Myc3–HPS4528–708 constructs, the desired portions of the HPS4 coding
region were ampliﬁed by PCR using the pCI-Myc3–HPS4 plasmid as
template. PCR products were sub-cloned into the EcoRI and XbaI sites of
the pCI-Myc3 vector. All the constructs were sequenced on both strands
to conﬁrm their identity and the presence of the desiredmutations, if ap-
plicable. Sequencing was performed using ABI BigDye Terminator chem-
istry (Applied Biosystems, Foster City, CA) with detection on an ABI 310
or a 3130xl Genetic Analyzer (Applied Biosystems). Electrophoregrams
were analyzed using Sequencher v4.9 software (Gene Codes Corporation,
Ann Arbor, MI).
2.5. Co-immunoprecipitations and Western blotting
Transfected cells were rinsed twice with ice-cold phosphate-
buffered saline (PBS) and incubated in 400 μl of lysis buffer [50 mM
Tris–HCl pH 7.4, 300 mM NaCl, 0.5% w/v Triton X-100, 5 mM EDTA,
0.1% BSA, 1× protease inhibitor cocktail (Roche, Indianapolis, IN)]. After
30 min of incubation at 4 °C, lysates were centrifuged at 16,000 ×g for
15 min. The supernatants were then pre-cleared by incubation for
60 min at 4 °C with G-Sepharose beads (Amersham Pharmacia Biotech,
Piscataway, NJ). The pre-cleared lysates were subsequently incubated
overnight at 4 °C with G-Sepharose beads and mouse monoclonal anti-
body against the speciﬁc tag. The beads were washed three times with
1 ml ice-cold lysis buffer and once with ice-cold PBS. Bound proteins
were eluted by boiling in 30 μl Laemmli buffer at 95 °C for 5 min. Sam-
ples were analyzed by SDS-PAGE and immunoblotting. SDS–PAGE analy-
sis and electroblotting onto nitrocellulose membranes was performed
using the NuPAGE® Bis-Tris Gel system (Invitrogen), according to the
manufacturer's instructions. Nitrocellulose membranes were incubated
with primary and horseradish peroxidase-labeled secondary antibodies
and reactive proteinsweredetectedusing ECLWesternBlotting Substrate
from Pierce (Rockford, IL).
2.6. Cell fractionation
To prepare cytosolic and membrane fractions, transfected cells
were washed twice in phosphate-buffered saline (PBS), detached by
scraping, suspended in buffer A (25 mM HEPES pH 7.4, 0.25 M sucrose,
1 mM EGTA, 0.5 EGTA, 1 mM dithiothreitol, and protease inhibitor cock-
tail). Cells weremechanically disrupted by successive passages through a
25-gauge needle. Extractswere centrifuged at 800 ×g for 10 min, and the
resulting post-nuclear supernatantswere then centrifuged at 120,000 ×g
for 45 min at 4 °C to yield cytosolic andmembrane fractions.Membranes
were resuspended in equal volume of buffer A containing 0.1% Triton-
X100. Both fractions were analyzed by immunoblotting.
2.7. Pulse-chase assay
The pEGFP-C1-HPS1 and HPS1 mutant constructs were transfected
in M1 cells using 1 μg of each plasmid. One day after transfection, cells
were washed with PBS and translation was inhibited using 100 μg/mL
cycloheximide and 40 μg/mL chloramphenicol in 1 mL of media. Sam-
ples were then collected at 0, 1, 3, and 6 h after translation inhibition.
Collected cells were lysed using 200 μl of lysis buffer. Equal volumes
of each sample were analyzed by SDS-PAGE and immunoblotting.
2.8. Immunoﬂuorescence Analysis
Transfected M1 cells were washed twice with PBS containing
Ca+2/Mg+2, ﬁxed in 4% PFA in PBS, and permeabilized for 10 min
with 0.2% (wt/vol) Triton X-100 in PBS. After permeabilization,
cells were blocked for 30 min with 0.2% (wt/vol) porcine skin gela-
tin in PBS and incubated in a humid chamber for 1 h at 37 °C with
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temperature, and incubated for 30 min at 37 °C with Alexa 488-
conjugated anti-rabbit IgG secondary antibody. Stained samples were
washed with PBS with Ca+2/Mg+2 and mounted on glass slides using
VECTASHIELD® (Vector Laboratories, Burlingame, CA). Images were
acquired on a Zeiss LSM510 META confocal laser-scanning microscope
(Carl Zeiss, Microimaging Inc., Thornwood, NY).
2.9. Treatment with PI3 kinase inhibitor
For each treatment, human ﬁbroblasts were grown in 24-well tissue
culture plates until approximately 95% conﬂuency and starved with
reduced serum Opti-MEM overnight. After overnight starvation, cells
were treated with PI3-kinase inhibitors (Wortmannin, LY294002) for
8 h. After treatments, cells were either washed with PBS Ca+2/Mg+2
and ﬁxed with 4% PFA to perform immunoﬂuorescence for HPS1 and
HPS4 or lysed for immunoblotting purposes.
3. Results
3.1. An HPS1 isoform encoded by a transcript lacking exon 9 interacts
with HPS4
Sequence analysis of the HPS1 cDNA products generated by RT-PCR
revealed a previously reported HPS1 transcript variant [20], that lacks
exon 9 (HPS1Δex9). We tested the distribution ofHPS1Δex9 in different
human tissues. PCR ampliﬁcation using a primer pair spanning the two
HPS1 transcripts revealed that the major HPS1 mRNA isoform ampliﬁed
as a 766-bp fragment, which was highly expressed in all tissues, as
expected [21]. TheHPS1Δex9 (667-bp fragment) isoformwas expressed
in tissues in which themajor HPS1 isoformwas expressed (Fig. 1A). Ad-
ditional bands seen in the RT-PCR analysis reﬂect ampliﬁcation of minor
splice variants,which are considered to beNMDsubstrates andwere not
considered in this study.
To determine whether the HPS1Δex9 protein product interacted
with HPS4, constructs coding for V5-tagged HPS1 and HPS1Δex9 pro-
teins were transiently transfected in M1 clone 26 cells expressing
Myc3-tagged HPS4. Tagged protein interactions were detected by
co-immunoprecipitation assays. HPS4 interacted with the HPS1 fullFig. 1. Expression and co-immunoprecipitation of HPS1Δex9. (A) Top. Schematic representa
splice variants. Bottom. A panel of ﬁrst-strand cDNAs derived from several human tissues (
transcripts were ampliﬁed as 766-bp (HPS1) and 667-bp (HPS1Δex9) fragments. β-Actin w
ﬁcation of minor splice variants. (B) Stably transfected M1 cells expressing Myc3-HPS4 (c
full-length or HPS1Δex9. An aliquot of these crude extracts corresponding to 1% of the m
against the V5 epitope and a mouse monoclonal antibody against the Myc tag. The crude
antibody against the Myc epitope. The immunoprecipitates were analyzed by 4–12% grad
V5 epitope. The positions of molecular weight markers are indicated on the left.length as well as with HPS1Δex9 (Fig. 1B), suggesting that the region
encoded by exon 9 (residues 256–289) is not required for the interac-
tionwith full-length HPS4. This result sparked our interest in determin-
ing which regions in each protein are important for the interaction
between HPS1 and HPS4 in BLOC-3.
3.2. Mapping of the HPS regions recognized by HPS4
To further deﬁne the region in HPS1 required for the interaction
with HPS4, we analyzed the predicted secondary structure of the pro-
tein (Network Protein Sequence Analysis of the Pôle Bio-informatique
Lyonnais). The candidate regions for interacting domains were select-
ed based on their predicted structural content. We generated ﬁve
HPS1 deletion constructs (Fig. 2A),that were GFP tagged and transiently
transfected in M1 clone 26 cells expressing Myc3-tagged HPS4. Co-
immunoprecipitation analysis revealed an interaction of HPS4 with
the N-terminus of HPS1 (residues 1–249) (Fig. 2B), suggesting that
this region of high α-helical content is critical for interaction with
full-length HPS4. Interestingly, the C-terminus of HPS1 (residues 506–
700) also showed interactionwithHPS4 (Fig. 2B). These results are con-
sistent with the presence of two regions in HPS1, located at the N- and
C-termini that are independently recognized byHPS4. As far aswe have
determined, no internal region of HPS1 is required to interact with
HPS4. Surprisingly, HPS1250–700 did not show any interaction with
HPS4, possibly due to autoinhibition of intermolecular binding by an in-
tramolecular interaction of the C-terminal region of HPS1 with a region
towards the N-terminal, as has been shown to occur with GGA1/3 [22]
and the kinesin-2 motor KIF17 [23].
3.3. Two separate binding sites in HPS4 are recognized by HPS1
A similar approach was used to identify the regions in HPS4 re-
sponsible for the interaction with HPS1. After analyzing the predicted
secondary structure of HPS4 (Fig. 3A), we generated a truncated HPS4
protein that contained amino acids 1–230, and two additional constructs
spanning residues 340–708 and 528–708 (Fig. 3A). Myc3-tagged HPS4
constructs were transiently transfected in M1 clone 5 cells expressing
HA3-tagged HPS1 (Fig. 3B). Co-immunoprecipitation of lysates from
transfected cells revealed an interaction of HPS1 with the ﬁrst 230tion of the HPS1 gene and location of the primers used for PCR analysis to detect HPS1
Clontech) was PCR ampliﬁed using a primer pair spanning exons 5–9. The two major
as utilized as loading control. Additional lower molecular weight bands reﬂect ampli-
lone number 26) were transiently transfected with constructs containing either HPS1
aterial available for IP, was analyzed by immunoblotting (IB) using a mouse antibody
extracts were used in immunoprecipitation (IP) reactions using a mouse monoclonal
ient SDS-PAGE followed by immunoblotting using a monoclonal antibody against the
Fig. 2. Divalent interaction of HPS1 with HPS4. (A) Top. The consensus secondary structure prediction for HPS1 as determined by the Network Protein Sequence Analysis of the Pôle
Bio-informatique Lyonnais. Blue areas represent α-helices, while red areas indicate predicted β-extended strand, and solid purple lines denote random coils. Bottom. GFP-tagged
HPS1 constructs used to map the HPS4 binding sites on HPS1 are represented by solid bars with residue numbers indicated on the left. (B) GFP-tagged HPS1 constructs were tran-
siently transfected into M1 clone 26 cells expressing Myc3-tagged HPS4. Coimmunoprecipitation analysis revealed an interaction of HPS4 with the ﬁrst 249 amino acids of HPS1,
suggesting that the N-terminus of HPS1 contains a region required for interaction with full-length HPS4. Interestingly, a construct containing the HPS1 C-terminus (HPS1506-700)
also displayed an interaction with HPS4. These results are consistent with HPS4 recognizing two different regions, located at the N-terminus (ﬁrst 249 amino acids) and the
C-terminus (506–700 amino acids) of HPS1. Co-immunoprecipitation with an irrelevant anti-HA antibody was used as control.
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in the interaction with full-length HPS1 (Fig. 3B). Interestingly, although
the N-terminus of the HPS4 is absent from the HPS4340–708 construct, an
interaction with HPS1 was nonetheless evident. No interaction was
observed when the HPS4528–708 construct was used (Fig. 3B). When the
partial overlap of constructs HPS4340–708 and HPS4528–708 is considered,
we can delineate an area between residues 340 and 528 of HPS4with rel-
atively low α-helix content as a second region recognized by HPS1. This
result suggests that the N-terminal and a central region of HPS4 are
important to interact with HPS1.3.4. The N-terminus of the HPS1 protein interacts with the N-terminus
of HPS4
Bioinformatic analyses suggested the presence of possible do-
mains at the N-terminus of HPS1 and HPS4 that could be importantfor the stability of their interaction [18,19]. To assess this possibility,
HeLa cells were co-transfected with vectors encoding Myc3-tagged
HPS4 truncations, i.e. HPS41–230 in combination with either GFP-
tagged HPS11–249 (N-terminus), HPS1250–505 (middle) or HPS1506–700
(C-terminus). Consistent with the results shown in Figs. 2 and 3,
Myc3-tagged HPS41–230 interacted only with the N-terminal region of
HPS1, but not with the middle or C-terminal regions of HPS1 (Fig. 4A).3.5. The central region of HPS4 protein interacts dually with either the N
or C-terminus of HPS1
We then analyzed the interactions of the HPS4 central region with
HPS1. To this end, we performed double transfections using vectors
encoding the Myc3-tagged HPS4 truncations HPS4340–708 and
HPS4528–708 in combination with either GFP-tagged HPS11–249,
HPS1250–505 or HPS1506–700. Myc3-tagged HPS4340–708 terminal
Fig. 3. HPS4 shows a dual interaction with HPS1. (A) Top. Consensus secondary structure prediction for HPS4 as determined using the Network Protein Sequence Analysis of the Pôle
Bio-informatique Lyonnais. Bottom. Three Myc3-tagged truncations of HPS4 are represented by solid bars with residue numbers indicated on the left. (B) Stably transfected M1
clone expressing HA3-HPS1 (clone 5) were transiently transfected with constructs coding for either full length Myc3-HPS4 or truncated proteins. Aliquots of the crude extracts cor-
responding to 1% of the material available for immunoprecipitation (IP) were analyzed by immunoblotting (IB) using an anti-Myc monoclonal antibody. The extracts were then
subjected to an IP with mouse monoclonal anti-Myc. The immunoprecipitates were analyzed by 4–12% gradient SDS-PAGE gel followed by immunoblotting using an antibody
against HA-coupled to horseradish peroxidase. IP with irrelevant mouse monoclonal antibodies against GFP was performed as control. The positions of molecular weight markers
are indicated on the left.
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central fragment (Fig. 4B). In contrast, no interaction was detected
with HPS4528–708, indicating that the C-terminal region of HPS4 does
not play a role in complex assembly (Fig. 4C). The results in Fig. 4C
corroborate the results shown in Fig. 3B, where the HPS4528–708 protein
failed to interact with the HPS1 fragments tested, indicating that the
C-terminal of HPS4 does not participate in the interaction with HPS1,
although we cannot exclude the possibility of this region participating
in complexes with other, unidentiﬁed proteins. Taken together, these
experiments show that the central region of HPS4 (residues 340–528)
interacts dually with either the N- or C-termini of HPS1.
3.6. Interacting regions of HPS1 and HPS4 exist as soluble and
membrane-associated forms
Full-length HPS1 and HPS4 exhibit a cytosolic distribution with
approximately 10% associated to membranes [14]. To test whether
this was also the case for the binding regions identiﬁed in the HPS1and HPS4 proteins, M1 cells were transfected with vectors encoding
either GFP-tagged HPS11–249, GFP-tagged HPS1506–700, Myc3-tagged
HPS41–230 or Myc3-tagged HPS4340–708. Cells were lysed in the absence
of detergents and soluble andmembrane fractions were isolated by dif-
ferential centrifugation. Immunoblot analysis using anti-GFP showed
that HPS11–249 localized mostly in the cytosol, while HPS1506–700 was
mainly membrane-associated (Fig. 5A). In the case of HPS4 fragments,
Myc3-tagged HPS41–230 and HPS4340–708 were recovered from both cy-
tosolic and membrane-associated (Fig. 5B) fractions. Consistent with
the results shown in Fig. 5A and B, immunoﬂuorescence microscopic
analysis agreed with the distribution found by immunoblot for each
HPS1 and HPS4 region analyzed (Fig. 5C–F), where the HPS11–249 local-
ized mostly in the cytosol, while HPS1506–700 was mainly membrane-
associated. In the case of Myc3-tagged HPS41–230 and HPS4340–708,
these two protein fragments share distribution between cytosol and
membrane-like structures. These observations suggest that the reported
membrane association of full-length HPS1 and HPS4 could be mediated
through the HPS1506–700, HPS41–230, and HPS4340–708 binding regions.
Fig. 4. Mutual interaction of the N-terminal fragments of HPS1 and HPS4, while the central region of HPS4 shows divalent interaction with the N- and C-termini of HPS1. To
delineate the structural determinants of the HPS1 and HPS4 interactions, HeLa cells were co-transfected with vectors encoding Myc3-tagged HPS41–230(A), HPS4340–708 (B) or
HPS4528–708 (C) truncations in combination with GFP-tagged HPS1 truncations representing N-terminal, middle and C-terminal portions of the protein. The Myc3-HPS4-N terminal
region interacts with the N-terminus of HPS1, but not with the C-terminus or the middle region of this protein. Myc3-tagged HPS4340–708 interacts with both the N- and the
C-termini of HPS1. The C-terminus of HPS4506–708 did not show any interaction with portions of the HPS1 protein.
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interact with HPS4
Following mapping of the regions required for BLOC-3 assembly,
we analyzed whether clinically relevant HPS1 truncated proteins
exhibit altered interaction with HPS4. To this end, we mimicked the
most common HPS1 mutation in the Puerto Rican population, i.e. an
insertion of 16 base pairs (c.1472_1487dup16), which causes disrup-
tion of the predicted secondary structure of the C-terminal domain of
the protein (p.H497QfsX90) and addition of 90 new amino acids due
to this frameshift mutation (Fig. 6A), while the ﬁrst 497 amino acids
remain intact. We inserted the 16-bp region into the cDNA re-
gion corresponding to exon 15 of the HA3-tagged HPS1 full-length
construct by site-directed mutagenesis. To test for physical association
between the HA-tagged truncated HPS1 (HA3–HPS116bp) and full-
length HPS4, epitope-tagged proteins were co-immunoprecipitated
under mild, nondenaturing conditions from lysates of transfected
M1 clone 26 cells. As shown in Fig. 6, Myc3–HPS4 was detected in
immunoprecipitates of both HA3–HPS1 and HA3–HPS116bp transfected
cells (Fig. 6B). Hence, the HPS1 N-terminus is sufﬁcient for the interac-
tionwith HPS4. These results suggest that the interactions of the N- and
C-termini of HPS1 may be independent from one another. The
interaction of the HA3–HPS116bp with HPS4 suggests that truncated
forms of HPS1 may retain partial function, which may be of clinical
relevance. Since the 16-bp duplication mutation is subject to
nonsense-mediated RNA decay (NMD) [24,25], we decided to inhibit
NMD by affecting the hSMG-1 kinase activity, a member of the PI3Kfamily, using wortmannin or LY294002. Human ﬁbroblasts from a
Puerto Rican HPS-1 patient homozygous for the 16-bp HPS1 duplication
were treated with different concentrations of wortmannin for 8 h
(Fig. 6C). Western Blot analysis against endogenous HPS1 showed a
faint lower molecular weight band after treatmentwith the hSMG-1 in-
hibitor,wortmannin; suggesting thepresence of truncated formofHPS1
(Fig. 6C). Treatment with wortmannin (data not shown) or LY294002
resulted in detection of HPS1 by immunoﬂuorescence in HPS-1 mutant
cells (Fig. 6D). Interestingly, the levels of HPS4 were restored in those
cells that showed positive staining for the truncated form of HPS1 (sim-
ilar results were obtained after treatment with wortmannin, data not
shown). These results suggest that truncated form of HPS1 can stabilize
endogenous HPS4, supporting the notion that the intact N-terminal of
the truncated form is able to complex with HPS4 endogenously.3.8. Proposed model of interaction between HPS1 and HPS4
Taken together, these co-immunoprecipitation results show that
the interactions between HPS1 and HPS4 are mainly stabilized by
their N-termini. The N-terminal residues of HPS1 are predicted to
form a structured region composed of β-sheets accompanied by
α-helices that resemble a DUF254 domain (a distant homolog of the
mu-adaptin longin domain found in clathrin adapter protein (AP)
complexes). The DUF254-like domain of HPS1 interacts with the
230 amino acids of the HPS4 N-terminal CHiPS-like domain (Fig. 7).
In addition, our data indicate that the unstructured middle region of
Fig. 5. HPS1 and HPS4 binding regions exist in soluble and membrane associated forms. Transfected M1 cells were mechanically disrupted by passing them through a 25-gauge
needle in buffer A. The crude lysates were centrifuged at 800 ×g and the resulting post-nuclear supernatants were centrifuged further to yield cytosolic (cyt) and membrane
(memb) fractions as described (Materials and methods). (A) The presence of GFP-HPS11–249, HPS1506–700 (upper panel) and (B) Myc3-HPS41–230, HPS4340–708 (upper panel) or
Lamp-2 (lower panel, integral membrane control) was assessed by immunoblotting. The positions of molecular weight markers are indicated on the left. Transfected M1 cells
were ﬁxed, and GFP tagged proteins were visualized directly (C and D) to detect GFP-HPS11–249, HPS1506–700. Transfected M1 cells were stained with mouse anti-Myc antibody
(E and F) to detect Myc3-HPS41–230 and HPS4340–708, followed by Alexa 488-conjugated anti-mouse IgG. Bar, 10 μm.
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(1–249) and C-terminal (506–700) region of HPS1.
3.9. Missense mutations within interacting regions of HPS1 alter its
stability
The proposed model of interaction between HPS1 and HPS4 was
tested by correlating the binding regions mapped in HPS1 with the
pathogenicity of HPS. We analyzed a series of missense mutations
found in HPS-1 patients, to determine whether these residues play
an important role in the assembly with HPS4 and stabilization of
the BLOC-3 complex. The substitutions introduced in HPS1 includ-
ed L239P, G313S, V547L, Y646C and E666K. The GFP-tagged HPS1
constructs containing these missense mutations were transiently
transfected in M1 cells stably expressing full length Myc3-tagged
HPS4. Coimmunoprecipitation experiments indicate that all mutants
interacted with Myc3–HPS4 in a manner similar to that of the HPS1
wild type construct (Fig. 8A). Since these missense substitutions did
not affect the association with HPS4, we examined the stability of
the HPS1 mutants by pulse-chase analysis. Transiently transfected
M1 cells were treated with chloroamphenicol and cycloheximide to
inhibit translation, and proteins were chased for different times (0,
1, 3, 6 h) at 37 °C. Equal amounts of total protein were resolved by
SDS-PAGE followed by Western blot analysis. Importantly, most of
the HPS1 mutants showed decreased stability compared to the wild
type protein (Fig. 8B–C), suggesting that alterations within regions
of interaction with HPS4 can affect the stability of the protein and
the proper formation of BLOC-3. These results support the notion
that these missense mutations are pathogenic, with the exception of
E666K, which did not show stability changes (Fig. 8B-C).4. Discussion
4.1. Discussion of results
The present work was undertaken to determine the domains in-
volved in the assembly and stabilization of BLOC-3. Our data demon-
strated that the product of the HPS1Δex9 transcript variant interacted
with HPS4. This interaction indicates that the exon 9 nucleotides
encoding residues 256–289 are not required for interaction with
HPS4. This isoform is expressed in all tissues examined and its in-
teraction with the major form of HPS4 suggests that interaction
between this HPS1 isoform and HPS4 may be physiologically signiﬁ-
cant. Western blot analysis of endogenous HPS1 yields typical doublet
bands, likely corresponding to the major and minor HPS1 isoforms
(79.3 kDa and 75.9 kDa) that result from alternative splicing of HPS
mRNA [21]. HPS1 doublet bands have been detected in HPS4 immu-
noprecipitates [16] suggesting that both isoforms are able to interact
with HPS4. Although additional experiments are needed, we propose
that HPS1Δex9 is the HPS1 isoform that corresponds to the minor
band that normally appears in Western blot analyses of endogenous
HPS1 [20], since the shorter transcript variant of HPS1 has a much
lower predicted molecular weight.
To deﬁne the binding regions in HPS1 and HPS4 required for the for-
mation of BLOC-3, we ﬁrst examined the predicted secondary structures
of both proteins. They eachhavewell-structuredN- andC-terminimainly
composed ofα-helices and β-strands connected by disordered segments
of different lengths. The N-termini of both proteins were predicted to
contain potential CHiPS or longin domains, respectively [18,19]. Co-
immunoprecipitation analysis showed assembly of the N-terminus of
each proteinwith its full-length partner.Moreover, expression of protein
Fig. 6. Co-immunoprecipitation of HA-tagged HPS1 and HPS1–16 bp. (A) The consensus secondary structure prediction for the wild type and the predicted mutant protein HPS116bp
was determined using the Network Protein Sequence Analysis of the Pôle Bio-informatique Lyonnais. Note that the predicted secondary structures of the N-terminus of wild type
and mutant HPS1 proteins are identical up to amino acid 500. The frameshift mutation in the HPS1 gene causes the loss of the last 200 amino acids compared to wild type HPS1 and
the addition of 89 new residues due to the resulting frameshift. Blue areas denote α-helices, red areas indicate predicted β-extended strand, and solid purple lines represent
random coils. (B) Stably transfected M1 cells expressing Myc3-HPS4 were transiently transfected with either HA3-HPS1 or HA3-HPS116bp. Aliquots of the extracts corresponding
to 1% of the material available for IP were analyzed by immunoblotting (IB) using an anti-HA mAb. The extracts were then subjected to an immunoprecipitation (IP) with
mouse monoclonal anti-HA as indicated. Irrelevant mouse monoclonal antibodies (GFP) were included as controls. The immunoprecipitates were analyzed by 4–12% SDS-PAGE
gradient gels followed by immunoblotting using an antibody against the Myc-tag. The positions of molecular weight markers are indicated on the left. Serum-starved HPS-1
skin ﬁbroblasts were treated with or without 20 μM wortmannin or LY294002 for 8 h in reduced serum medium. (C) Western blot analysis of HPS1 from cell extracts after
wortmannin treatment. Proteins (100 μg per lane) extracted with cell lysis buffer were separated by SDS-PAGE (4–12%) in the presence of β-mercaptoethanol and transferred
to nitrocellulose membranes. Treatment with different concentrations of wortmannin suppressed phosphorylation of Akt (control of treatment). A faint band of the expected mo-
lecular weight of 64 kDa was observed after treatment with 20 μM wortmannin, corresponding to the truncated form of HPS1 (D) Fibroblasts were ﬁxed with 4% PFA, non speciﬁc
sites were blocked and a dual incubation with mouse monoclonal anti-HPS1 and rabbit polyclonal anti-HPS4 was performed for 30 min in a humid chamber. Staining with second-
ary Alexa 488-conjugated goat anti-mouse and Alexa 555-conjugated goat anti-rabbit for 30 min. Treatment with LY294002 for 8 h showed an intracellular expression of truncated
form of HPS1 and a restoration of HPS4 protein as compared with untreated defective cells. Bar, 10 μm.
Fig. 7. Proposed model for the interaction of HPS1 and HPS4. The results of the
co-immunoprecipitation analyses (Figs. 1–4 and 6) are consistent with a model
where the N- and C-termini of HPS1 and the N-terminal and middle region of HPS4
are involved in the interactions, leading to BLOC-3 formation. Speciﬁcally, N-termini
of HPS4 and HPS1 interact with each other, and the central portion of HPS4 interacts
with both the N- and the C-termini of HPS1.
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interacted with the N-terminus of HPS1, indicating that both possible
domains are related and required for the formation of BLOC-3. Interest-
ingly, these proteins showed a second region of interaction. The HPS1
C-terminus assembled with HPS4340–708, but not with HPS4528–708.
Excluding the overlapping amino acid residues between these two HPS4
constructs, we proposed that the interaction of the HPS1–C-terminus is
mediated by the middle region of HPS4 comprised by residues 340–528.
Despite recent evidence suggesting that the central region of HPS4
is not involved in the interaction with HPS1 [17], we showed that
this region in HPS4, predicted to be relatively unstructured, plays an
important role in BLOC-3 formation. Also, the middle region in HPS4
appears to interact with the N-terminus of HPS1. Hence, the poorly
conserved and unstructured region in HPS4 appeared to be responsi-
ble for dual interactions with both the N- and C-termini of HPS1.
This result indicates that both proteins are involved in a series of
interdomain interactions, where the HPS1 N- and C-terminal and
the middle portions of HPS4 are expected to assume a compact
structure.
Our results are generally consistent with previous studies on HPS1–
HPS4 interactions [17], except that we did not ﬁnd any participation of
Fig. 8.Missense mutations in HPS1 within putative interacting regions cause protein instability. (A) M1 cells expressing Myc3-HPS4 were transiently transfected with GFP-HPS1 or
GFP-HPS1 constructs containing mutations identiﬁed in HPS patients. Aliquots of the extracts representing 1% of the material available for IP were analyzed by immunoblotting (IB)
using anti-GFP. The extracts were then subjected to an immunoprecipitation (IP) with mouse monoclonal anti-Myc as indicated. Irrelevant IgG were included as controls. The
immunoprecipitates were analyzed by 4–12% SDS-PAGE gradients followed by immunoblotting using an antibody against GFP. The positions of molecular weight markers are in-
dicated on the left. (B) Transiently transfected M1 cells were treated with chloroamphenicol and cycloheximide. Proteins were chased for different periods (0, 1, 3, and 6 h) at 37 °C.
Equivalent amounts of homogenate were resolved by SDS-PAGE followed by western blotting. (C) Bands were quantiﬁed using ImageJ 1.44 software and the percentage of each
mutant at each chase time was calculated relative to time zero (T0).
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even though the C-terminus of HPS4 is well-organized and a previous
study suggested its participation [17]. The discrepancy between our
results and other published studies [17] may be due to the different
approaches (in vitro solubility/aggregation and proteolysis studies of
puriﬁed full length proteins expressed in insect cells or truncated pro-
teins expressed in bacteria, versus, co-immunoprecipitations of tagged
proteins expressed in human cell lines) used to determine the regions
that participate in the interactions. We chose to evaluate the HPS1–
HPS4 interactions by co-immunoprecipitation because this approach
was successfully used with epitope-tagged proteins to assemble and
form BLOC-3 [14,15]. Overexpression of proteins can trigger aggrega-
tion and thus raise concerns of false interactions being detected. Our
experiments were performed using the soluble portion of the whole
cell lysates to avoid artifacts caused by aggregated proteins, which are
usually found in the insoluble fraction. In addition, our truncated pro-
tein forms demonstrate cytosolic and/ or membrane-associated pat-
terns with low degree of aggregation. The endogenous HPS1 and HPS4
protein have been described to be mainly cytosolic with approximately
10% associated to membranes [14–16]. To this end, we are conﬁdent
that the interactions we are detecting are of physiologic relevance and
not artifacts of aggregation events. Other approaches, that shouldinclude structural studies, have to be examined in order to conﬁrm
our ﬁndings.
Our data support the hypothesis thatmembrane association of HPS1
and HPS4 depends upon speciﬁc regions of these proteins. Speciﬁcally,
the N-terminal portion of HPS1 is mostly cytosolic, with a small fraction
associated with membranes; the C-terminus was found mainly in
the membrane fraction. The HPS4 fragments at the N- and C-termini
(HPS41–230 and HPS4340–708) were found in both the cytosolic and
membrane fractions. Previous studies have shown that the HPS1–
HPS4 complex is mainly cytosolic, with a small membrane-bound frac-
tion [14], and that endogenous HPS1 associates with tubulovesicular
and pre-melanosome structures [21]. The role of HPS1membrane asso-
ciation and its implication in the biogenesis of lysosome-related organ-
elles remains to be determined.
In vitro assays with the truncated HPS116bp, mimicking the com-
mon mutation found in Puerto Rican HPS-1 patients, showed interac-
tion with HPS4, suggesting the possibility to generate BLOC-3 in these
patients after creating a truncated form of HPS1. To corroborate the
in vitro ﬁnding, we used small molecules such as wortmannin and
LY24002 to impair the NMD pathway and generate a truncated HPS1
protein in skin ﬁbroblasts derived from an HPS-1 patient homozygous
for the 16-bp duplication. We found that after inhibiting NMD, a
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levels of HPS4 were restored. Interactions of HPS4 with truncated
form of HPS1 may be mediated through the N-terminus region of
HPS1, since HPS116bp retains an intact N-terminus compared to the
wild type. This supports the notion that lacking one of the two binding
region inHPS can be compensated partially by the other binding region.
Although the BLOC-3-like complexmay have decreased stability andwe
did not test its functionality or other biochemical properties, these re-
sults warrant examination of the functionality of truncated forms of
HPS1 in patient cells using smallmolecules or other genetic approaches.
Other missense mutations of HPS-1 patients, located within the
regions that interact with HPS4, also retained their ability to interact
with HPS4 but, in general, had decreased stability. These mutations
presumably disrupt the structure of BLOC-3, leading to degradation,
which explains the pathogenesis in patients harboring homozygous
missense mutations in HPS1. Patients carrying missense mutations
in the binding regions (e.g., L668P) manifest a moderate disease phe-
notype [26]. It is possible that a mutation in one of the two binding
regions of HPS1 may be compensated by the other interacting region,
allowing BLOC-3 to form but with decreased stability.
5. Conclusions
Our experiments demonstrate that the molecular determinants of
the HPS1–HPS4 interaction reside in the N- and C-termini of HPS1 and
in the N-terminal and middle region of HPS4. These novel protein in-
teraction domains may also function in other proteins. In addition,
these ﬁndings support the possibility of generating a truncated form
of BLOC-3 that could potentially retain partial functionality. Structural
and functional studies are needed to better understand the nature of
BLOCs and their roles in the pathogenesis of HPS.
Clinically, since HPS1 requires two interacting regions to stabilize
HPS4 in BLOC-3 formation, the rest of the protein may be favorably
manipulated by molecular approaches to generate a truncated form
of HPS1 that retains the required interacting regions. Generation of
truncated proteins has been successfully applied in patients, where
the truncated protein retains function and restores the missing func-
tion [27–29]. HPS1 mutations in regions that are not required for the
interaction with HPS4, such as the 16-bp duplication mutation, found
1 in 1,800 Puerto Ricans in the northwest region of the island, may be
a good target. Hopefully, generation of a truncated form of HPS1 in
patients can partially restore the missing function and may impact
the development of the pulmonary ﬁbrosis associated with the lack
of this protein in HPS-1 patients. Further studies are needed to deter-
mine if this approach may be translated to an effective therapy for
this life-threatening complication in HPS-1 and HPS-4.
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